FDA approves Avastin for priority review, improves outlook on treatment. Roche Group's Genentech led study on 452 women with recurrent, persistent or metastatic types of cervical cancer.
Roche Group's Avastin for cervical cancer given priority review status by FDA
Tech Times - 16 Jul 2014 12:23
FDA approves Avastin for priority review, improves outlook on treatment. Roche Group's Genentech led study on 452 women with recurrent, persistent or metastatic types of cervical cancer.
Share this Article
Recommended